arrow
F

Friedrich Foerster

johannes gutenberg university of mainz
H指数:31
被引数:5,540

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer

EORTC-1607-GITCG/ABC-09:西吉姆联合帕博利珠单抗治疗晚期或转移性胆道癌的开放标签、单臂II期首线研究

2026-08-010
PRE
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry

免疫检查点抑制剂治疗后肝细胞癌患者的肝移植——来自跨国LITCHI登记研究的数据

2026-05-190
OAAI
Multicenter Study of Bleeding- and Thromboembolic-Events with Durvalumab ± Tremelimumab versus Atezolizumab and Bevacizumab in Advanced HCC: A Retrospective Analysis

多中心研究:在晚期HCC中,度鲁特玛±曲美木单抗与阿替利珠单抗和贝伐珠单抗的出血和血栓栓塞事件比较:一项回顾性分析

2026-03-110
OAAI
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity

阿特珠单抗/贝伐珠单抗治疗肝细胞癌的早期死亡率与肝功能受损及全身免疫改变相关

2025-07-010
OAAI
Extracapsular tumor spread does not influence survival outcomes in resected N1-patients with intrahepatic cholangiocarcinoma– a retrospectively controlled cohort study

囊外肿瘤扩散不影响肝内胆管癌N1患者切除后的生存结局——一项回顾性对照队列研究

2025-05-110
OA
13C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
2022-09-063
OAAI
pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages
2022-03-1526
OAAI